Literature DB >> 25786378

Reachable workspace reflects dynamometer-measured upper extremity strength in facioscapulohumeral muscular dystrophy.

Jay J Han1, Evan De Bie1, Alina Nicorici1, Richard T Abresch1, Ruzena Bajcsy2, Gregorij Kurillo1,2.   

Abstract

INTRODUCTION: It is not known whether a reduction in reachable workspace closely reflects loss of upper extremity strength in facioscapulohumeral muscular dystrophy (FSHD). In this study we aimed to determine the relationship between reachable workspace and quantitative upper extremity strength measures.
METHODS: Maximal voluntary isometric contraction (MVIC) testing of bilateral elbow flexion and shoulder abduction by hand-held dynamometry was performed on 26 FSHD and 27 control subjects. In addition, Kinect sensor-based 3D reachable workspace relative surface areas (RSAs) were obtained. Loading (500-g weight) effects on reachable workspace were also evaluated.
RESULTS: Quantitative upper extremity strength (MVIC of elbow flexion and shoulder abduction) correlated with Kinect-acquired reachable workspace RSA (R = 0.477 for FSHD, P = 0.0003; R = 0.675 for the combined study cohort, P < 0.0001). Progressive reduction in RSA reflected worsening MVIC measures. Loading impacted the moderately weak individuals the most with additional reductions in RSA.
CONCLUSIONS: Reachable workspace outcome measure is reflective of upper extremity strength impairment in FSHD.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  FSHD; Kinect; dynamometry; reachable workspace; upper extremity

Mesh:

Year:  2015        PMID: 25786378      PMCID: PMC4575235          DOI: 10.1002/mus.24651

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  20 in total

Review 1.  Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Curr Opin Neurol       Date:  2011-10       Impact factor: 5.710

2.  A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score.

Authors:  Costanza Lamperti; Greta Fabbri; Liliana Vercelli; Roberto D'Amico; Roberto Frusciante; Emanuela Bonifazi; Chiara Fiorillo; Carlo Borsato; Michelangelo Cao; Maura Servida; Francesca Greco; Rita Di Leo; Leda Volpi; Claudia Manzoli; Paola Cudia; Ebe Pastorello; Leopoldo Ricciardi; Gabriele Siciliano; Giuliana Galluzzi; Carmelo Rodolico; Lucio Santoro; Giuliano Tomelleri; Corrado Angelini; Enzo Ricci; Laura Palmucci; Maurizio Moggio; Rossella Tupler
Journal:  Muscle Nerve       Date:  2010-08       Impact factor: 3.217

3.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit.

Authors:  J C van Deutekom; C Wijmenga; E A van Tienhoven; A M Gruter; J E Hewitt; G W Padberg; G J van Ommen; M H Hofker; R R Frants
Journal:  Hum Mol Genet       Date:  1993-12       Impact factor: 6.150

4.  Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group.

Authors:  K E Personius; S Pandya; W M King; R Tawil; M P McDermott
Journal:  Phys Ther       Date:  1994-03

5.  Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy.

Authors:  D D Kilmer; R T Abresch; M A McCrory; G T Carter; W M Fowler; E R Johnson; C M McDonald
Journal:  Am J Phys Med Rehabil       Date:  1995 Sep-Oct       Impact factor: 2.159

6.  The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy.

Authors:  O F Brouwer; G W Padberg; R J van der Ploeg; C J Ruys; R Brand
Journal:  Brain       Date:  1992-10       Impact factor: 13.501

7.  Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey M Statland; Michael P McDermott; Chad Heatwole; William B Martens; Shree Pandya; E L van der Kooi; John T Kissel; Kathryn R Wagner; Rabi Tawil
Journal:  Neuromuscul Disord       Date:  2013-02-11       Impact factor: 4.296

Review 8.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

9.  Development and application of stereo camera-based upper extremity workspace evaluation in patients with neuromuscular diseases.

Authors:  Gregorij Kurillo; Jay J Han; Richard T Abresch; Alina Nicorici; Posu Yan; Ruzena Bajcsy
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

10.  Reference values for isometric muscle force among workers for the Netherlands: a comparison of reference values.

Authors:  Rob Kw Douma; Remko Soer; Wim P Krijnen; Michiel Reneman; Cees P van der Schans
Journal:  BMC Sports Sci Med Rehabil       Date:  2014-02-25
View more
  4 in total

1.  Longitudinal study of upper extremity reachable workspace in fascioscapulohumeral muscular dystrophy.

Authors:  Maya N Hatch; Kiin Kim; Gregorij Kurillo; Alina Nicorici; Craig M McDonald; Jay J Han
Journal:  Neuromuscul Disord       Date:  2019-05-23       Impact factor: 4.296

2.  Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy.

Authors:  Jay J Han; Evan de Bie; Alina Nicorici; Richard T Abresch; Colleen Anthonisen; Ruzena Bajcsy; Gregorij Kurillo; Craig M Mcdonald
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 3.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

4.  Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.

Authors:  Samantha LoRusso; Nicholas E Johnson; Michael P McDermott; Katy Eichinger; Russell J Butterfield; Elena Carraro; Kiley Higgs; Leann Lewis; Karlien Mul; Sabrina Sacconi; Valeria A Sansone; Perry Shieh; Baziel van Engelen; Kathryn Wagner; Leo Wang; Jeffrey M Statland; Rabi Tawil
Journal:  BMC Neurol       Date:  2019-09-10       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.